SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer

被引：0
|
作者：
Montal, R. [1 ]
Merche, M. -V. [1 ]
Anta, B. [2 ]
Martinez, N. [2 ]
Santos, C. [1 ,3 ]
Sanjuan, X. [4 ]
Paules, M. J. [5 ]
Perez Martin, F. J. [6 ]
Azuara, D. [3 ]
Salazar, R. [1 ,3 ]
Rojas, J. M. [2 ]
机构：
[1] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[2] Inst Salud Carlos III UFIEC, Majadahonda, Spain
[3] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] HUB, IDIBELL, Interdisciplinary Comm Esophagogastr Tumours, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol ICO LHospitalet, IDIBELL, Clin Res Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-195
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Microenvironment targets in KRAS-mutated metastatic colorectal cancer
    Marchio, Serena
    Bartolini, Alice
    Cardaci, Sabrina
    Soster, Marco
    Corti, Giorgio
    Lamba, Simona
    Bussolino, Federico
    Cora', Davide
    Nicolantonio, Federica D.
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Advanced therapies on BRAF-mutated and KRAS-mutated metastatic colorectal cancer
    LI Zi-nan
    YU Li-feng
    WANG Jia-qi
    NIU Yan-xin
    WANG Xin-yu
    ZHAO Lin
    中国药理学与毒理学杂志, 2019, (10) : 883 - 883
  • [3] Prediction of response to FOLFOX in metastatic colorectal cancer by mtTFA
    Yoshida, Y.
    Hasegawa, J.
    Nezu, R.
    Kim, Y.
    Hirota, M.
    Yoshikawa, K.
    Ohashi, H.
    Kawano, K.
    Izumi, H.
    Kohno, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
    Yone, You
    Abdallah, Mohammad
    Tahir, Saad Sabih
    Cellek, Selim
    Zhang, Jufen
    Lester, Yvonne
    Shillito, Lauren
    Child, Jennifer
    Dawson, Lizzie
    Singizi, Bryan
    Bustin, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
    Zocche, David M.
    Ramirez, Carolina
    Fontao, Fernando M.
    Costa, Lucas D.
    Redal, Maria A.
    FRONTIERS IN GENETICS, 2015, 6
  • [6] Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer
    Chan, E.
    Ayers, G. D.
    Goff, L.
    McClanahan, P.
    Holloway, M.
    Ciombor, K.
    Smith, S. J.
    Ancell, K.
    Cardin, D. B.
    Berlin, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S549 - S549
  • [7] Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.
    Boursi, Ben
    Shacham-Shmueli, Einat
    Lawrence, Yaacov Richard
    Yang, Yu-Xiao
    Reiss, Kim Anna
    Golan, Talia
    Mamtani, Raashi
    Halpern, Naama
    Aderka, Dan
    Giantonio, Bruce
    Margalit, Ofer
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Lawrence, Yaacov R.
    Yang, Yu-Xiao
    Reiss, Kim A.
    Golan, Talia
    Mamtani, Raashi
    Halpern, Naama
    Aderka, Dan
    Giantonio, Bruce
    Boursi, Ben
    CLINICAL COLORECTAL CANCER, 2019, 18 (03) : E300 - E307
  • [9] An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer
    Epperla N.
    George B.
    Journal of Gastrointestinal Cancer, 2016, 47 (2) : 206 - 209
  • [10] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
12345